

Synthesis and Characterization of trisubstituted 4,5-dihydropyrazoles and evaluated for their antimicrobial activity

KM. Dipika^{1*}, Dr. Arun Patel², Dr. Shailendra Patel³, Dr. Aditya Sahu⁴

^{1,2,3,4}SRGI- Shri Ram Group of Institution, Department of pharmacy, Jabalpur-482002Madhya Pradesh, India

*Corresponding Author: KM. DIPIKA

Email ID: dubeydeepika194@gmail.com, Mobile No.: 9682082131

Abstract:

Pharmaceutical chemistry is predominantly focused on drug discovery and development. Among the vast array of bioactive compounds, α,β -unsaturated ketones, particularly chalcones, represent an essential class of naturally occurring flavonoids with diverse pharmacological properties. In this study, different 4-substituted benzaldehydes, specifically (4-fluorophenyl) hydrazine and (4-chlorophenyl) hydrazine, were utilized to synthesize a series of novel trisubstituted 4,5-dihydropyrazole derivatives. The synthesized compounds were structurally characterized using standard spectroscopic techniques, confirming the successful formation of the targeted heterocyclic frameworks. The antimicrobial activity of these new derivatives was evaluated against various bacterial strains. Results indicated that the compounds exhibited a spectrum of antimicrobial efficacy ranging from mild to significant, with the trisubstituted 4,5-dihydropyrazole derivatives bearing amine terminations displaying superior antimicrobial activity when compared to standard drugs. This suggests their potential as potent antimicrobial agents. The findings emphasize the need for continued optimization in drug design strategies to enhance antimicrobial potency across a broader range of bacterial strains. Additionally, future work should involve testing these novel compounds in diverse biological assays to explore their therapeutic potential in other areas, such as anti-inflammatory and anticancer activities, particularly against carcinoma cell lines. This study underscores the importance of synthetic heterocyclic compounds in the development of novel therapeutics.

Keywords: Pharmaceutical Chemistry, Drug Discovery, A,B-Unsaturated Ketone, Chalcones, Trisubstituted 4,5-Dihydropyrazoles, Antimicrobial Activity, Heterocyclic Compounds, Synthetic Chemistry, Antibacterial Agents, Anti-Inflammatory, Anticancer

Introduction

The pharmaceutical chemistry or the medicinal chemistry is at the intersection of chemistry and pharmacology involving the designing, synthesizing, identifying and developing of new chemical entities suitable for therapeutic use.^[1] In the early stages of the medicinal chemistry scientists isolated medicinal agents found in plants. Now, scientists in this field are creating new synthetic compounds as drugs.^[2] Pharmaceutical chemistry is almost always geared toward drug discovery and development. Heterocyclic compounds are the most complex branches of organic chemistry that have been studied extensively and attracted attention of medicinal and pharmacological activities.^[3] The chemistry of heterocyclic compounds is interesting because many natural products and drugs belong to this group. Heterocyclic compounds are cyclic organic substances which contain in the ring system at least one atom other than carbon. Many alkaloids, vitamins, antibiotics, synthetic medicines and dyestuffs are heterocyclic derivatives.^[4]

The α,β -unsaturated ketone-chalcone is an important class of naturally occurring flavonoid compounds^[5], Flavonoids and chalcones are natural antioxidants present in plants and preventing oxidativedamages of the cell.^[6] Chalcones are intermediates for the synthesis of a large number of bioactive molecules, such as pyrazolines and pyrazole derivatives.^[7] The high medicinal significance of this scaffold has attracted considerable attention from many researchers and encouraged the design and synthesis of numerous Pyrazole containing compounds with diverse pharmacological activities, such as antibacterial.^[8]

Furthermore, thiazole compounds exhibiting a promising biological potential for the treatment of Alzheimer's disease and metabolic syndrome have been reported in the scientific literature. Nowadays, research in the field of antimicrobial drug design is focused on the discovery of novel targets and chemical entities that possess antibacterial activity in order to overcome the rapid development of drug resistance.^[10] The few antibiotics that have been recently approved are structurally related to older drugs, being susceptible to the same mechanisms of resistance.

Experimental

4.1 Materials and method


The substituted 1-(4-aminophenyl)ethan-1-one, ethanol and potassium hydroxide was purchased from Sigma Aldrich, India. The different 4-substituted benzaldehyde, (4-fluorophenyl)hydrazine and (4-chlorophenyl)hydrazine were purchased from sigma Aldrich. All the chemicals were purchased from Sigma Aldrich India. Commercial grade solvents

used for the reactions were distilled before use. The melting points of the synthesized compounds were determined in open glass capillaries. IR spectra were recorded on Bruker-alpha FTIR spectrometer. Elemental analysis was performed and found values were within 0.4% of theoretical values. ¹HNMR spectra were recorded at 400 MHz, Mass Spectra were recorded using Mass Spectrometers Jeol FSX-112 (FAB) by ESI.

4.2 Synthesis scheme

Synthetic strategy planning for synthesis

(a) Synthesis of (E)-1-(4-substituted phenyl)-3-(p-substituted)prop-2-en-1-one




Procedure: A 1-(4-aminophenyl)ethan-1-one (0.002M)(1) was added to an ethanolic solution(0.002M of KOH in 40 mL ethanol 96%) and stirred for 15 min, then (0.002M) of 4-substituted benzaldehyde(2) was added drop wise to the solution and stirred at room temperature for 48 hrs. The TLC method is utilized to monitor the reaction progress using n-hexane: ethyl acetate as solvent system.^[63] The reaction mixture was poured into ice-cold water, solidformed(3) was filtered, washed several times with the ice-cold water and dried at room temperature. Percentage yield was found to be 85.20%.

Table 4.1: Quantity of chemicals taken

S. NO.	Name of Chemicals	Mol. formula	Mol. Weight	Quant. (gm)
1.	1-(4-aminophenyl)ethan-1-one	C ₈ H ₉ NO	135.17	2.70
2.	1-(4-chlorophenyl)ethan-1-one	C ₈ H ₇ ClO	154.59	3.09
3.	4-chlorobenzaldehyde	C ₇ H ₅ ClO	140.57	2.81
4.	4-bromobenzaldehyde	C ₇ H ₅ BrO	185.02	3.70
5.	4-fluorobenzaldehyde	C ₇ H ₅ FO	124.11	2.48
6.	4-nitrobenzaldehyde	C ₇ H ₅ NO ₃	151.12	3.02

(b) Synthesis of 1-(4-substitutedphenyl)-3-(4-substitutedphenyl)-5-(p-substituted)-4,5-dihydro-1H-pyrazole



Procedure:

The different substituted compounds 3 (0.01M) was dissolved in 10 ml methanol under stirring, and take (4-fluorophenyl)hydrazine and (4-chlorophenyl)hydrazine (Compound 4, 0.02M) in beaker and added 10 ml of methanol and 2ml of concentrated sulfuric acid to dissolve the content. Both the solution was mixed in round bottom flask and stirring for 48h at room temperature. The reaction was monitored by the TLC technique using N-hexane: methanol (7:2). The obtained solution was poured into crushed ice, then the solution was evaporated to obtain the pyrazoline product^[64] (Compound 5). The compound coded as TDHP-1 to TDHP-12.

Table 4.2: Quantity of chemicals taken

S. NO.	Name of Chemicals	Mol. Formula	Mol. Weight	Quant(gm)
1.	(E)-3-(4-aminophenyl)-1-(4-chlorophenyl)prop-2-en-1-one	C ₁₅ H ₁₂ ClNO	257.72	2.57
2.	(E)-3-(4-aminophenyl)-1-(4-bromophenyl)prop-2-en-1-one	C ₁₅ H ₁₂ BrNO	302.17	3.02
3.	(E)-3-(4-aminophenyl)-1-(4-fluorophenyl)prop-2-en-1-one	C ₁₅ H ₁₂ FNO	241.27	2.41
4.	(E)-3-(4-aminophenyl)-1-(4-nitrophenyl)prop-2-en-1-one	C ₁₅ H ₁₂ N ₂ O ₃	268.27	2.68
5.	(E)-1,3-bis(4-chlorophenyl)prop-2-en-1-one	C ₁₅ H ₁₀ Cl ₂ O	277.14	2.77
6.	(E)-1-(4-bromophenyl)-3-(4-chlorophenyl)prop-2-en-1-one	C ₁₅ H ₁₀ BrClO	321.60	3.21
7.	(E)-3-(4-chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one	C ₁₅ H ₁₀ ClFO	260.69	2.60
8.	(E)-3-(4-chlorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one	C ₁₅ H ₁₀ ClNO ₃	287.70	2.87
9.	(4-fluorophenyl)hydrazine	C ₆ H ₇ FN ₂	126.13	2.52
10.	(4-chlorophenyl)hydrazine	C ₆ H ₇ ClN ₂	142.59	2.85

4.3 Characterization of the synthesized compounds

4.3.1 List of Synthesized compounds: In this thesis, a total of sixteen substances were synthesized (Table 4.3) and purified using column chromatography. The IR, ¹HNMR spectroscopy, mass, and elemental analyses were used to analyze the synthesized compounds.

Table 4.3: List of Final synthesized compounds

SN	Code	Chemical name
1.	TDHP-1	4-(3-(4-chlorophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
2.	TDHP-2	4-(3-(4-bromophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
3.	TDHP-3	4-(1,3-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
4.	TDHP-4	4-(1-(4-fluorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
5.	TDHP-5	4-(1,3-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
6.	TDHP-6	4-(3-(4-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
7.	TDHP-7	4-(1-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
8.	TDHP-8	4-(1-(4-chlorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline
9.	TDHP-9	3,5-bis(4-chlorophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole
10.	TDHP-10	3-(4-bromophenyl)-5-(4-chlorophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole
11.	TDHP-11	5-(4-chlorophenyl)-1,3-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazole
12.	TDHP-12	5-(4-chlorophenyl)-1-(4-fluorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole
13.	TDHP-13	1,3,5-tris(4-chlorophenyl)-4,5-dihydro-1H-pyrazole
14.	TDHP-14	3-(4-bromophenyl)-1,5-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazole
15.	TDHP-15	1,5-bis(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole
16.	TDHP-16	1,5-bis(4-chlorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole

Qualitative analysis


- (a) **Melting point-** Open capillary tubes were used to determine the melting point of the produced compounds, Electro Thermal Stuart SMP3 advanced melting point apparatus as stated in Table 4.4.
- (b) **Solubility-** At room temperature (18-30°C), the solubility of the produced product was tested in various solvents. Table 4.5 shows the solubility of the produced chemical.

- (c) **Elements test (Lassaigne's test):** Each compound's sodium fusion extract was produced and evaluated for nitrogen, sulphur, and halogens. All of the produced compounds tested positive for nitrogen, sulphur, and halogen [146].
- (d) **Bromine test for un-saturation:** With continual shaking, dissolve the synthesised final chemical in a suitable solvent and add 4-5 drops of bromine water. The presence of a brown colour discharge indicates that the chemical was unsaturated and that a double bond was present. Wherever possible, the synthesized compounds were submitted to qualitative analyses for nitrogen, sulphur, and halogen. Elemental vario EL III Carlo-Erba 1108 was used for quantitative examination of nitrogen, oxygen, and sulphur.
- (e) **IR spectra** were recorded on Bruker alpha-II software. FT-IR spectrometer apparatus used to provide detailed information about the structural changes in the region (4000–400 cm⁻¹).
- (f) **NMR spectra** were recorded on C13 Advance Bruker DRX 400 MHz spectrometer. ¹H-NMR apparatus used to determine the proton spectra of compounds. The spectra recorded in deuterated solvent CDCl₃ in 400 MHz at 25 °C or by DMSO-d₆ solvent in 300MHz at 21°C. Chemical shifts (δ) are given in parts per million (ppm) downfield relative to tetramethyl silane TMS.
- (g) **Mass spectra** were recorded on JeolSx 102/DA-6000 mass spectrometer using fast moving bombardment (FAB) technique.
- (h) TLC (Thin-layer chromatography) plastic sheets silica gel, 20*20 cm, layer thickness 0.2 mm, was carried out on eluted with an ethyl acetate/n-hexane mixture, the spots were detected by UV light which monitored the progress of the reaction.

S. NO.	Code	Chemical formula	Mol. Weight	Percent Yield	Melting point
1.	TDHP-1	C ₂₁ H ₁₇ ClFN ₃	365.84	88%	125-127°C
2.	TDHP-2	C ₂₁ H ₁₇ BrFN ₃	410.29	76%	132-134°C
3.	TDHP-3	C ₂₁ H ₁₇ F ₂ N ₃	349.38	82%	145-147°C
4.	TDHP-4	C ₂₁ H ₁₇ FN ₄ O ₂	376.39	70%	114-116°C
5.	TDHP-5	C ₂₁ H ₁₇ Cl ₂ N ₃	382.29	68%	122-124°C
6.	TDHP-6	C ₂₁ H ₁₇ BrClN ₃	426.74	62%	112-114°C
7.	TDHP-7	C ₂₁ H ₁₇ ClFN ₃	365.84	65%	150-152°C
8.	TDHP-8	C ₂₁ H ₁₇ ClN ₄ O ₂	392.84	60%	138-140°C
9.	TDHP-9	C ₂₁ H ₁₅ Cl ₂ FN ₂	385.26	69%	115-117°C
10.	TDHP-10	C ₂₁ H ₁₅ BrClFN ₂	429.72	70%	162-164°C
11.	TDHP-11	C ₂₁ H ₁₅ ClF ₂ N ₂	368.81	65%	193-195°C
12.	TDHP-12	C ₂₁ H ₁₅ ClFN ₃ O ₂	395.82	78%	113-115°C
13.	TDHP-13	C ₂₁ H ₁₅ Cl ₃ N ₂	401.72	62%	123-125°C
14.	TDHP-14	C ₂₁ H ₁₅ BrCl ₂ N ₂	446.17	75%	117-119°C
15.	TDHP-15	C ₂₁ H ₁₅ Cl ₂ FN ₂	385.26	68%	121-123°C
16.	TDHP-16	C ₂₁ H ₁₅ Cl ₂ N ₃ O ₂	412.27	72%	127-129°C

4.5 CHARACTERIZATION OF THE SYNTHESIZED COMPOUNDS BY IR, NMR, MASS AND ELEMENTARY ANALYSIS

COMPOUND CODE: TDHP-1



IUPAC NAME: 4-(3-(4-chlorophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline

Chemical Formula: C₂₁H₁₇ClFN₃;

Molecular Weight: 365.84

Elemental analysis:

Elements	C	N	F	Cl
Calculated	68.95	11.49	5.19	9.69
Found	68.92	11.45	5.20	9.66

IR (cm⁻¹):

3066 (C-H), 3446 (N-H); 2901(C-H), 1688 (C=C), 1597 (C-C), 1464 (C=N), 1301 (C-H), 740 (C-Cl)

¹HNMR (ppm):

δ 8.40, 7.72, 7.51, 7.23 (m, 4H, CH=CH-CH=CH), 7.03, 7.53, 7.49, 7.40 (m, 4H, Ph-H), 3.02, 2.99 (d, 2H, C-4, CH₂), 3.45 (d, 1H, C-5, CH), 2.05, 1.90, 1.87, 1.76 (m, 15H), 11.431 (s, 1H, NH)

FAB Mass (m/z): 365.80




Fig. 1: FT-IR spectrum of compound TDHP-1





Fig. 2: ¹HNMR spectrum of compound TDHP-1

COMPOUND CODE: TDHP-2



IUPAC NAME:4-(3-(4-bromophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl) aniline

Chemical Formula: C₂₁H₁₇BrFN₃;**Molecular Weight:** 410.29**Elemental analysis:**


Elements	C	N	F	Br
Calculated	61.48	10.24	4.63	19.47
Found	61.45	10.20	4.60	19.45

IR (cm⁻¹):

3012 (C-H), 2912(C-H), 1675 (C=C), 1595 (C-C), 1462(C=N), 1308(C-H), 745 (C-Cl),1018 (C-Br); 1102 (C-F)

¹HNMR (ppm):


δ 8.40-7.23 (m, 4H, CH=CH-CH=CH), 7.03-7.53 (m, 4H, Ph-H), 2.99-3.02 (d, 2H), 3.45 (d, 1H),11.431 (s, 1H, NH)

FAB Mass (m/z): 410.25**COMPOUND CODE: TDHP-3****IUPAC NAME:** 4-(1,3-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline**Chemical Formula:** C₂₁H₁₇F₂N₃;**Molecular weight:** 349.38**Elemental analysis:**

Elements	C	N	F
Calculated	72.19	12.03	10.88
Found	72.15	12.00	10.85

IR (cm⁻¹):

3286 (C-H), 2899 (C-H), 3446 (N-H), 1737 (C=C), 1616 (C-C), 1447 (C=N),1134(C-H); 1102 (C-F)

¹HNMR (ppm):δ 7.187-8.621(m, 4H, CH=CH-CH=CH), 7.55-8.373 (m, 3H), 2.470 (d, 2H, CH₂), 3.304 (d, 1H, CH), 11.40 (s, 1H, NH).**FAB Mass (m/z): 349.30****COMPOUND CODE: TDHP-4****IUPAC Name:**4-(1-(4-fluorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline**Chemical Formula:** C₂₁H₁₇FN₄O₂;**Molecular weight:** 376.39**Elemental analysis:**

Elements	C	N	F
Calculated	67.01	14.89	5.05
Found	67.00	14.85	5.02

IR (cm⁻¹):

3286 (C-H), 2899 (C-H), 3446 (N-H), 1737 (C=C), 1616 (C-C), 1447(C=N),(1512 (N=O), 1334 (N-O), 1134 (C-H); 1102 (C-F)

¹HNMR (ppm):

δ 7.18-8.62(m, 4H, CH=CH-CH=CH), 7.50-8.35 (m, 3H, Ar-H), 2.470 (d, 2H), 3.304 (d, 1H), 11.431 (s, 1H, NH).

FAB Mass (m/z): 376.14




Fig. 3: FT-IR spectrum of compound TDHP-4





Fig. 4: ¹HNMR spectrum of compound TDHP-4

COMPOUND CODE: TDHP-5



IUPAC name: 4-(1,3-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline

Chemical Formula: C₂₁H₁₇Cl₂N₃;

Molecular Weight: 382.29

Elemental analysis:


Elements	C	N	Cl
Calculated	65.98	10.99	18.55
Found	65.90	10.95	18.52

IR (cm⁻¹):

3062(C-H), 2905(C-H), 1688 (C=C), 3446 (N-H); 1597 (C-C), 1460(C=N), 1301 (C-H), 740 (C-Cl), (3333, OH, C₂H₅OH)

¹HNMR (ppm):

7.20-8.38 (m, 4H, CH=CH-CH=CH), 7.02-7.50 (m, 4H), 2.95-3.00 (d, 2H), 3.42 (d, 1H), 11.431 (s, 1H, NH)

FAB Mass (m/z): 382.08**COMPOUND CODE: TDHP-6**

IUPAC NAME: 4-(3-(4-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline

Chemical Formula: C₂₁H₁₇BrClN₃;

Molecular weight: 426.74

Elemental analysis:

Elements	C	N	Cl	Br
Calculated	59.11	9.85	8.31	18.72
Found	59.12	9.80	8.29	18.70


IR (cm⁻¹):

3060(C-H), 3446 (N-H); 2908 (C-H), 1688 (C=C) 1597 (C-C), 1464 (C=N), 1301(C-H), 740 (C-Cl), 1018 (C-Br);

¹HNMR (ppm):

δ 7.20-8.50 (m, 4H, CH=CH-CH=CH), 7.02-7.53 (m, 4H, Ph-H), 3.05, 2.97 (d, 2H, CH₂), 3.45 (d, 1H, C-5, CH); 11.431 (s, 1H, NH)

FAB Mass (m/z): 426.70

COMPOUND CODE: TDHP-7

IUPAC NAME: 4-(1-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline

Chemical Formula: C₂₁H₁₇ClF₃N₃;


Molecular weight: 365.84

Elemental analysis:

Elements	C	N	F	Cl
Calculated	68.95	11.49	5.19	9.69
Found	68.92	11.45	5.15	9.65

IR (cm⁻¹):


3066 (C-H), 2901 (C-H), 1688 (C=C), 1597(C-C),1464 (C=N), 1301 (C-H), 740(C-Cl),1102 (C-F), 1018 (C-Br)

¹HNMR (ppm):7.12-8.36 (m, 4H, CH=CH-CH=CH), 7.01-7.48 (m, 4H, Ph-H), 3.05, 2.95 (d, 2H, CH₂), 3.54 (d, 1H, CH), 11.431 (s, 1H, NH)**FAB Mass (m/z):** 365.80**COMPOUND CODE: TDHP-8****IUPAC name:** 4-(1-(4-chlorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline**Chemical Formula:** C₂₁H₁₇ClN₄O₂;**Molecular weight:** 392.84**Elemental analysis:**

Elements	C	N	Cl
Calculated	64.21	14.26	9.02
Found	64.18	14.25	9.05

IR (cm⁻¹):

3150 (C-H), 2902(C-H), 3446 (N-H), 1650 (C=C)1585 (C-C), 1465 (C=N),1512 (N=O), 1334 (N-O), (1250, C-H bend), 740(C-Cl)


¹HNMR (ppm):δ 7.23-8.62 (m, 4H, CH=CH-CH=CH), 7.03-8.80 (m, 3H, Ar-H), 3.08, 2.47 (d, 2H, CH₂), 3.42 (d, 1H, C-5, CH), 11.431 (s, 1H, NH).**FAB Mass (m/z):**392.60**COMPOUND CODE: TDHP-9****IUPAC NAME:** 3,5-bis(4-chlorophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole**Chemical Formula:** C₂₁H₁₅Cl₂FN₂;**Molecular weight:** 385.26

Elemental analysis:

Elements	C	N	F	Cl
Calculated	65.47	7.27	4.93	18.40
Found	65.45	7.25	4.90	18.35

IR (cm⁻¹):


3066 (C-H), 2901(C-H), 1688 (C=C), 1597 (C-C), 1464 (C=N), 1301 (C-H), 740 (C-Cl), 1102 (C-F)

¹HNMR (ppm):δ 7.20-8.45 (m, 4H, CH=CH-CH=CH), 7.03-7.53(m, 4H, ph-H), 3.08, 2.82 (d, 2H, CH₂), 3.45 (d, 1H, CH)**FAB Mass (m/z):** 385.20**COMPOUND CODE: TDHP-10****IUPAC NAME:** 3-(4-bromophenyl)-5-(4-chlorophenyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole**Chemical Formula:** C₂₁H₁₅BrClFN₂;**Molecular Weight:** 429.72**Elemental analysis:**

Elements	C	N	F	Br	Cl
Calculated	58.70	6.52	4.42	18.59	8.25
Found	58.65	6.50	4.40	18.57	8.20

IR (cm⁻¹):

3066 (C-H), 2901 (C-H), 1688 (C=C), 1597 (C-C), 1464 (C=N), 1301 (C-H), 740 (C-Cl), 1102 (C-F); 1018 (C-Br)

¹HNMR (ppm):δ 7.20-8.45 (m, 4H, CH=CH-CH=CH), 7.03-7.53(m, 4H, ph-H), 3.08, 2.82 (d, 2H, CH₂), 3.45 (d, 1H, CH)**FAB Mass (m/z):** 429.70**COMPOUND CODE: TDHP-11****IUPAC NAME:** 5-(4-chlorophenyl)-1,3-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazole**Chemical Formula:** C₂₁H₁₅ClF₂N₂;**Molecular Weight:** 368.81**Elemental analysis:**

Elements	C	N	Cl	F
Calculated	68.39	7.60	9.61	10.30
Found	68.35	7.56	9.58	10.30


IR (cm⁻¹):

3066 (C-H), 2901 (C-H), 1688 (C=C), 1597 (C-C), 1464 (C=N), 1301 (C-H), 740 (C-Cl), 1102 (C-F)

¹H NMR (ppm):

δ 7.25-8.40 (m, 4H, CH=CH-CH=CH), 7.05-7.53 (m, 4H, Ph-H), 3.05, 2.95 (d, 2H, CH₂), 3.54 (d, 1H, CH),

FAB Mass (m/z): 368.20

COMPOUND CODE: TDHP-12

IUPAC NAME: 5-(4-chlorophenyl)-1-(4-fluorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole

Chemical Formula: C₂₁H₁₅ClFNO₃

Molecular weight: 395.82

Elemental analysis:

Elements	C	N	F	Cl
Calculated	63.72	10.62	4.80	8.96
Found	63.70	10.60	4.38	8.95


IR (cm⁻¹):

3150 (C-H), 2902 (C-H), 3446 (N-H), 1650 (C=C) 1585 (C-C), 1465 (C=N), 1512 (N=O), 1334 (N-O), (1250, C-H bend), 740(C-Cl)

¹H NMR (ppm):

δ 7.23-8.62 (m, 4H, CH=CH-CH=CH), 7.03-8.80 (m, 3H, Ar-H), 3.08, 2.47 (d, 2H, CH₂), 3.42 (d, 1H, C-5, CH), 11.431 (s, 1H, NH)

FAB Mass (m/z): 395.80

COMPOUND CODE: TDHP-13

IUPAC NAME: 1,3,5-tris(4-chlorophenyl)-4,5-dihydro-1H-pyrazole

Chemical Formula: C₂₁H₁₅Cl₃N₂

Molecular weight: 401.72

Elemental analysis:

Elements	C	N	Cl
Calculated	62.79	6.97	26.47
Found	62.75	6.95	26.45


IR (cm⁻¹):

3066 (C-H), 2901 (C-H), 1688 (C=C), 1597 (C-C), 1464 (C=N), 1301 (C-H), 740 (C-Cl), 1102 (C-F)

¹H NMR (ppm):

δ 7.20-8.45 (m, 4H, CH=CH-CH=CH), 7.03-7.53(m, 4H, ph-H), 3.08, 2.82 (d, 2H, CH₂), 3.45 (d, 1H, CH)


FAB Mass (m/z): 401.20

COMPOUND CODE: TDHP-14**IUPAC NAME:** 3-(4-bromophenyl)-1,5-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazole**Chemical Formula:** C₂₁H₁₅BrCl₂N₂;**Molecular Weight:** 446.17**Elemental analysis:**

Elements	C	N	Cl	Br
Calculated	56.53	6.28	15.89	17.91
Found	56.50	6.25	15.82	17.90

IR (cm⁻¹):

3066 (C–H), 2901 (C–H), 1688 (C=C), 1597 (C–C), 1464 (C=N), 1301 (C–H), 740 (C–Cl)


¹HNMR (ppm):δ 7.20-8.45 (m, 4H, CH=CH-CH=CH), 7.03-7.53(m, 4H, ph-H), 3.08, 2.82 (d, 2H, CH₂), 3.45 (d, 1H, CH)**FAB Mass (m/z):** 446.10**COMPOUND CODE: TDHP-15****IUPAC NAME:** 1,5-bis(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole**Chemical Formula:** C₂₁H₁₅Cl₂FN₂;**Molecular Weight:** 385.26**Elemental analysis:**

Elements	C	N	F	Cl
Calculated	65.47	7.27	4.93	18.40
Found	65.45	7.25	4.90	18.35

IR (cm⁻¹):

3066 (C–H), 2901 (C–H), 1688 (C=C), 1597 (C–C), 1464 (C=N), 1301 (C–H), 740 (C–Cl); 1102 (C–F)

¹HNMR (ppm):δ 7.20-8.45 (m, 4H, CH=CH-CH=CH), 7.03-7.53(m, 4H, ph-H), 3.08, 2.82 (d, 2H, CH₂), 3.45 (d, 1H, CH)**FAB Mass (m/z):** 385.20

COMPOUND CODE: TDHP-16**IUPAC NAME:** 1,5-bis(4-chlorophenyl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole**Chemical Formula:** C₂₁H₁₅Cl₂N₃O₂**Molecular weight:** 412.27**Elemental analysis:**

Elements	C	N	Cl
Calculated	61.18	10.19	17.20
Found	61.15	10.15	17.15

IR (cm⁻¹):

3150 (C-H), 2902 (C-H), 3446 (N-H), 1650 (C=C) 1585 (C-C), 1465 (C=N), 1512 (N=O), 1334 (N-O), (1250, C-H bend), 740(C-Cl)

¹HNMR (ppm):δ 7.23-8.62 (m, 4H, CH=CH-CH=CH), 7.03-8.80 (m, 3H, Ar-H), 3.08, 2.47 (d, 2H, CH₂), 3.42 (d, 1H, C-5, CH), 11.431 (s, 1H, NH)**FAB Mass (m/z):** 412.20**4 RESULT AND DISCUSSION****Chemistry**

IR, NMR, mass spectral, and elemental studies were used to characterize the target structures of the synthesized compounds. The 1-(4-aminophenyl)ethan-1-one (0.002M) (**1**) react with 4-substituted benzaldehyde (**2**) to form (**E**)-**1**-(4-substituted phenyl)-3-(p-substituted)prop-2-en-1-one[Compound **3**]. The Compound **3** obtained as yellow crystal product having the melting point 115-117°C. The final compound (**compound4**), **1**-(4-substitutedphenyl)-3-(4-substitutedphenyl)-5-(p-substituted)-4,5-dihydro-1H-pyrazolewas synthesized by the reaction of compound **3** with different 4-fluorophenyl)hydrazine and (4-chlorophenyl)hydrazine. The physicochemical properties of the synthesized compound (TDHP-1 to TDHP-16) was represented in Table 4.4.

The synthesized compounds have characterized by the IR, ¹HNMR and mass spectral analysis. The IR spectrum of the compounds has shown the characteristics peak (cm⁻¹) at 3012 (C-H), 2912 (C-H), 1675 (C=C), 1595 (C-C), 1462 (C=N), 1308 (C-H), 1512 (N=O), 1334 (N-O), 745 (C-Cl), 1018 (C-Br); 1102 (C-F). The ¹HNMR spectra of Synthesized compounds depicted the peak of δ 7.23-8.62 (m, 4H, CH=CH-CH=CH), 7.03-8.80 (m, 3H, Ar-H), 3.08, 2.47 (d, 2H, CH₂), 3.42 (d, 1H, C-5, CH), 11.431 (s, 1H, NH). Compound **1** (TDHP-1), mass spectrum have shown peak at m/z = 365.84, which matches the chemical formula C₂₁H₁₇ClFN₃. All the other synthesized compound has also shown the molecular ion peak similar to their molecular formula and weight.

5.0 PHARMACOLOGICAL EVALUATION**Antimicrobial Activity**

Microorganisms require nutrition for all their metabolic activities. They draw the nutrition from their surrounding area. The growth of the microorganisms depends on the type of the nutrition they utilize. Resistance of pathogenic bacteria to available antibiotics is quickly becoming a major problem in the community and hospital based healthcare settings. Antimicrobials are one of the very important categories of drug. It is quite clear from its wide use that these categories of drugs are very important from the medical point of view.^[65] However, microbial resistance towards the drug creates a very serious problem because of development of resistance; many drugs are now useless which were very effective in the past. Moreover, the toxic effects produced by these antibiotics are also reducing their significance.^[66]

There is a need for new antimicrobial agents for resisting microbial infections. Antimicrobial (antibacterial and antifungal) activity of the synthesized compounds was done by disc diffusion method.

Minimum Inhibitory Concentration (MIC)

Minimum Inhibitory Concentration (MIC) is the lowest concentration of an antimicrobial that inhibit the visible growth of a microorganism after overnight incubation. MIC values can be determined by a number of standard test procedures. The most commonly employed methods are the broth dilution method and agar dilution methods. In agar dilution

method, the diluted compounds were inoculating into bacterial growth media, incubated and scored for growth. This procedure is a standard assay for antimicrobials.^[67] MIC is important in diagnostic laboratories to confirm resistance of micro organisms to an antimicrobial agent and also to monitor the activity of new antimicrobial agents. MIC is generally regarded as the most basic laboratory measurement of the activity of an antimicrobial agent against an organism.^[68] Clinically, the minimum inhibitory concentrations are used not only to determine the amount of antibiotic that the patient will receive but also the type of antibiotic used, which in turn lowers the opportunity for microbial resistance to specific antimicrobial agents.

Materials used in Microbiology Assays

Gram-negative bacteria species *Pseudomonas aeruginosa* (ATCC/27853), *Salmonella typhimurium* (ATCC/25922). Gram-positive bacteria species *Bacillus subtilis* and *Staphylococcus aureus* (ATCC/25923). All microorganisms were obtained from Agricultural biological laboratory. (10 μ g) of gram-negative bacteria (*Gentamycin*) and (10 μ g) of gram-positive bacteria (*Meropenem*) are used as antibiotic standards, normal saline 0.9%, Mueller Hinton agar media (MHA).

Test Microorganisms

The synthesized compounds (TDHP-1 to TDHP-16) were tested for their antimicrobial activity against gram-negative bacteria species (*Pseudomonas Aeruginosa* and *Salmonella typhimurium*), gram-positive bacteria species (*Bacillus subtilis* and *Staphylococcus aureus*).

Preparation of Stock Solution

Against gram-negative and gram-positive bacteria species, 50 μ g/ml drug concentration in DMSO were prepared and tested against standard drug concentration i.e. (10 μ g) of gram-negative bacteria (*Gentamycin*) and (10 μ g) of gram-positive bacteria (*Meropenem*) are used as antibiotic standards.^[69]

Antibacterial Activity by Disc Diffusion Method

Gram-negative and gram-positive bacteria species were used as antibacterial test strains. The synthesized compounds (TDHP-1 to TDHP-16) were screened at the concentration (500 μ g/mL) in DMSO on the agar media for all bacterial strains. The antibiotic *Gentamycin* was used as standard drugs against gram negative bacteria. *Meropenem* was used as standard drugs against gram positive bacteria. The plate inoculated with bacteria was incubated for 24 h at 37°C. After the period of incubation, the zone of inhibition produced by the test compounds was measured in mm. The screening tests were performed in triplicate and the results were taken as a mean of three determinations. **Figure 5.1** shows the evaluation of antibacterial activity by disc diffusion method.




Fig 5.1: Schematic representation of Agar/ Disk diffusion method

The tested samples diffuse through the agar around its disks and inhibit germination of the microorganism by a characteristics zone of inhibition depending on the microorganism sensitivity to the test sample, then measuring the inhibition zones diameters in mm.

RESULT AND DISCUSSION

Evaluation of Antibacterial Activity of synthesized compounds

The Zone of Inhibition results of the synthesized compounds against gram negative bacteria species *Pseudomonas aeruginosa*, and *Salmonella typhimurium*, gram positive bacteria species such as *Bacillus subtilis* and *Staphylococcus aureus*. The investigation of the antibacterial screening of the test compound (TDHP-1 to TDHP-16) revealed that all these compounds exhibited different degrees of antibacterial activity in relation to the tested microbial species and showed moderate to weak antibacterial activity against all the organisms against both of two types of bacterial strain. The results of MIC's determined reveal that the test compounds can act as a good anti-bacterial agent at higher concentrations, and no inhibition zone at lower concentration (Table 5.1).

Table 5.1: Zone of Inhibition of the synthesized compounds against bacterial species in mm.

Antibiotic	Gram Positive Bacteria		Gram Negative Bacteria	
	<i>Bacillus subtilis</i>	<i>Staphylococcus aureus</i>	<i>Pseudomonas aeruginosa</i>	<i>Salmonella typhimurium</i>
Meropenem	30	28	-	-
Gentamycin	-	-	25	20
TDHP-1	22.7	23.4	22.5	19.2
TDHP-2	22.6	22.5	21.3	19.5
TDHP-3	28.5	21.4	21.5	16.3
TDHP-4	25.5	20.2	21.8	14.2
TDHP-5	29.5	23.5	21.4	18.3
TDHP-6	27.2	24.8	22.4	15.6
TDHP-7	23.5	22.5	22.9	14.2
TDHP-8	24.5	26.5	21.7	13.5
TDHP-9	12.5	12.5	12.5	13.8
TDHP-10	13.0	12.8	14.6	13.6
TDHP-11	18.0	13.6	14.2	11.5
TDHP-12	16.5	14.6	13.5	10.2
TDHP-13	12.3	15.6	13.4	9.2
TDHP-14	12.2	13.4	13.5	9.5
TDHP-15	13.5	12.3	13.2	8.9
TDHP-16	14.6	12.8	13.8	8.7

The Sixteen synthesized compounds (TDHP-1 to TDHP-16) were evaluated for the antibacterial screening and data obtained by the result stated that substituted pyrazoline derivatives has shown the mild to better activity against tested organism's strains. The screening carried out on both Gram positive and gram-negative bacteria separately.




Fig. 5.1: The pictorial representation of Zone of inhibition of compound against gram-positive bacteria (*Micrococcus luteus* ATCC 9341)

The Data of antibacterial activity against the gram-positive bacterial strains (*Bacillus subtilis* and *Staphylococcus aureus*) suggested that among substituted pyrazoline derivatives (TDHP-1 to TDHP-16), compound TDHP-9, TDHP-10, TDHP-13, TDHP-14 and TDHP-15 have shown mild activity while as compound TDHP-11, TDHP-12, TDHP-16 and TDHP-1 shown moderate activity and compound TDHP-2, TDHP-3, TDHP-4, TDHP-5, TDHP-6, TDHP-7, TDHP-8 have shown best activity against gram positive bacteria (Table 5.1).




Fig. 5.2: The pictorial representation of Zone of inhibition of compound against gram negative bacteria

The Data of antibacterial activity against the gram-negative bacterial strains (*Salmonella typhimurium* and *Pseudomonas aeruginosa*) suggested that among substituted pyrazoline derivatives (TDHP-1 to TDHP-16), compound TDHP-9, TDHP-13, TDHP-14, TDHP-15 have shown mild activity while as compound TDHP-10, TDHP-11, TDHP-16 shown moderate activity and compound TDHP-1, TDHP-2, TDHP-3, TDHP-4, TDHP-5, TDHP-6, TDHP-7, TDHP-8 have shown best activity against gram negative bacteria.

Conclusions

The research work described the synthesis of new chemical entities of pyrazole derivatives. The synthesized compounds were characterized by standard spectroscopic techniques. The evaluation of the antimicrobial activity of all new compounds was carried out against bacterial strains and proven to have significant to mild to better activity. In general trisubstituted 4,5-dihydropyrazoles derivatives having amine termination has shown the better anti-microbial activity as compared to standard drug. There is a need in drug design strategy to achieve more anti-microbial potency in different bacterial strain on novel future synthetic heterocyclic compounds. Moreover, there is a need for other ways to test these compounds on various assays for additional therapeutic areas like inflammatory and carcinoma cell lines as well.

REFERENCES

1. Fioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R. Inhibitors of Yellow Fever Virus replication based on 1, 3, 5-triphenyl-4,5-dihydropyrazole scaffold: design, synthesis and antiviral evaluation. *Eur J Med Chem* 2017; 141: 15–25.
2. Jimi MA, Raj K. 4,5-Dihydro-1H-pyrazole: An indispensable scaffold. *J Enzyme Inhib Med Chem* 2014; 29: 427–442.
3. RamirezPrada J, Robledo SM, Velez ID, Crespo MDP, Quiroga J, Abonia R, Montoya A, Svetaz L, Zacchino S, Insuasty B. Synthesis of novel quinoline-based 4,5-dihydro-1H-pyrazoles as potential anticancer, antifungal, antibacterial, antiprotozoal agents. *Med Chem* 2017; 131: 237–254.
4. Sowmya DV, Lakshmi Teja A, Padmaja A, Kamala Prasad V, Padmavathi V. Green approach for the synthesis of thiophenyl pyrazoles and isoxazoles by adopting 1,3 dipolar cycloaddition methodology and their antimicrobial activity. *Eur J Med Chem* 2018; 143: 891–898.
5. Palapati K, Venkata RK, Afzal BS. Antitubercular evaluation of isoxazole appended 1-carboxamido-4,5-dihydro-1H-pyrazoles. *J Res Pharm* 2019; 23: 156–163.
6. Lavanya G, Mallikarjunareddy L, Padmavathi V, Padmaja A. Synthesis and antimicrobial activity of (1,4-phenylene)bis(arylsulfonylpyrazoles and isoxazoles). *Eur J Med Chem* 2014; 73: 187–194.
7. Abdelhamid AO, El Sayed IE, Zaki YH, Hussein AM, Mangoud MM, Hosny MA. Utility of 5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide in the synthesis of heterocyclic compounds with antimicrobial activity. *Biorg Med Chem* 2019; 13: 48.
8. Hassan SY. Synthesis, antibacterial and antifungal activity of some new pyrazoline and pyrazole derivatives. *Molecules* 2013; 18: 2683–2711.

9. Hai-Chao W, Xiao-Qiang Y, Tian-Long Y, Hong-Xia L, Zhong-Chang W, Hai-Liang Z. Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors. *Molecules* 2016; 21: 1012
10. Vanessa G, Sidnei M, Alex FCF, Darlene CF, Pio C, Ernani P. Antioxidant and Antimicrobial Properties of 2-(4,5-Dihydro-1H-pyrazol-1-yl)-pyrimidine and 1-Carboxamidino-1H-pyrazole Derivatives. *J Braz Chem Soc* 2010; 21: 1477–1483.
11. Shah Z, MohammedZ, Hingole A. An introduction of some novel pyrazolinesto synthetic chemistry and antimicrobial studies. *JChem Pharma Res*2010; 2(6): 441-445.
12. GencY, Ozkanca R, Bekdemir Y. Antimicrobial activity of some sulfonamide derivatives on clinical isolates of *Staphylococcus aureus*. *Ann. Clin. Microbiol. Antimicrob.* 2008; 7(1): 1–6
13. Gul HI, Yamali C, Yesilyurt F, Sakagami H, KucukogluK, Gulcin I, Gul M, Supuran CT. Microwave-assisted synthesis and bio-evaluation of new sulfonamides. *J Enzyme Inhib Med Chem* 2017; 32(1): 369–374.
14. Hamada NMM, Abdo NYM. Synthesis, characterization, antimicrobial screening and free-radical scavenging activity of some novel substituted pyrazoles. *Molecules* 2015; 20(6):10468–10486.
15. Khanam S, Dar H, Siddiqui AM, Rehman N. Synthesis, characterization, antimicrobial and anticancer studies of new steroidal pyrazolines. *J Saudi Chem Soc* 2015; 20(1): 7-12.
16. Mishra VK, Mishra M, Kashaw V, Kashaw SK. Synthesis of 1,3,5-trisubstituted pyrazolines as potential antimalarial and antimicrobial agents. *Bioorg. Med. Chem.* 2017; 25(6): 1949–1962.
17. Samshuddin S, Narayana B, Sarojini BK, Khan MTH, Yathirajan HS, Raj CGD, Raghavendra R. Antimicrobial, analgesic, DPPH scavenging activities and molecular docking study of some 1,3,5-triaryl-2-pyrazolines. *Med Chem Res* 2012; 21 (8), 2012-2022.
18. Thach TD, Le T, Nguyen TA, Dang CH, Dang VS, Nguyen TD. Synthesis of sulfonamides bearing 1,3,5-triarylpyrazoline and 4-thiazolidinone moieties as novel antimicrobial agents. *J Serb Chem Soc* 2020; 85(2), 155–162.
19. Akhtar W, Marella A, Alam MM, Khan MF, Akhtar M, Anwer T, Khan F, Naematullah M, Azam F, Rizvi MA, Shaquiquzzaman M. Design and synthesis of pyrazole pyrazoline hybrids as cancer-associated selective COX-2 inhibitors. *Arch Pharm* 2021; 354 (1): 2000116.
20. Jain SK, Singhal R, Jain NK. Synthesis, characterization and biological activity of pyrazoline derivatives. *Res J Pharm Tech* 2021; 14(12):6223-7.
21. Moqbel RMA, Gitima D, Meriyam V M. Synthesis and molecular docking studies of some new pyrazoline derivatives for antimicrobial properties. *Res J Pharm Tech* 2020; 13(10): 4629-34.
22. Thach TD, Le T, Nguyen TA, Dang CH, Dang VS, Nguyen TD. Synthesis of sulfonamides bearing 1,3,5-triarylpyrazoline and 4-thiazolidinone moieties as novel antimicrobial agents. *J Serb Chem Soc* 2020; 85(2): 155–162.
23. Prabha T, Aishwaryah P, Manickavalli E, Chandru R, Arulbharathi G, Anu A, Sivakumar T. A Chalcone Annulated Pyrazoline Conjugates as a Potent Antimycobacterial Agents: Synthesis and in Silico Molecular Modeling Studies. *Research J Pharm Tech* 2019; 12(8): 3857-65.
24. Ozmen Ozgun D, Gul HI, Yamali C, Sakagami H, Gulcin I, Sukuroglu M, Supuran CT. Synthesis and bioactivities of pyrazoline benzene-sulfonamide as carbonic anhydrase and acetylcholinesterase inhibitors with low cytotoxicity. *Bioorg. Chem.* 2019; 84: 511–517.
25. Kumar P, Kumar A, Nayak P, Pinto JS, D'Souza B. Synthesis and Antimicrobial Evaluation of some Novel Pyrazoline Incorporated Pyrrole Derivatives. *Research J Pharm Tech* 2018; 11(6): 2460-2462.
26. Kumari R, Kumar A. Synthesis and In-Vitro Anti-Inflammatory Activity of New Pyrazoline Derivatives. *Research J Pharm Tech* 2018; 11(9): 3969-3972
27. Naim MJ, Alam O, Alam MJ, Hassan MQ, Siddiqui N, Naidu VGM, Alam MI. Design, synthesis and molecular docking of thiazolidinedione based benzene sulfonamide derivatives containing pyrazole core as potential anti-diabetic agents. *Bioorg Chem* 2018; 76: 98–112.
28. Ansari A, Ali A, Mohammad A. Biologically active pyrazole derivatives. *New J Chem* 2017; 41(1): 16-41.
29. Bhat KI, Kumar A. Synthesis and Biological Evaluation of Some Novel Pyrazoline Derivatives Derived from Chalcones. *Research J Pharm Tech* 2017; 10(5): 1344-1346.
30. Revanasiddappa BC, Vijay Kumar M, Nayak P, Ali AR, Jisha MS. Synthesis, Antibacterial and Antifungal Evaluation of Novel Pyrazoline Derivatives. *Research J Pharm Tech* 2017; 10(5): 1481-1484.
31. Fernandes J, Revanasiddappa BC, Bhat KI, Vijay Kumar M, D'Souza L, Alva SS. Synthesis and in-Vitro Anti-Inflammatory Activity of Novel Pyrazoline Derivatives. *Research J Pharm Tech* 2017; 10(6):1679-1682.
32. Khazaal & Tomma. Synthesis and Characterization of Novel Schiff Bases Containing Isoxazoline or Pyrazoline Unit. *Ibn AL-Haitham Journal for Pure and Applied Science* 2017; 24(2): 338-345.
33. Fioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R. Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: design, synthesis and antiviral evaluation. *Eur J Med Chem* 2017; 141: 15–25.
34. Gul HI, Mete E, Taslimi P, Gulcin I, Supuran CT. Synthesis, carbonic anhydrase I and II inhibition studies of the



- 1,3,5-trisubstituted-pyrazolines. *J Enzyme Inhib Med Chem* 2017; 32(1): 189–192.
35. Mishra VK, Mishra M, Kashaw V, Kashaw SK. Synthesis of 1, 3, 5 trisubstituted pyrazolines as potential antimalarial and antimicrobial agents. *Bioorg. Med. Chem.* 2017; 25(6): 1949–1962.
36. Sadashiva R, Naral D, Kudva J, Shivalingegowda N, Lokanath NK, Pampa KJ. Synthesis, spectral, biological activity, and crystal structure evaluation of novel pyrazoline derivatives having sulfonamide moiety. *Med Chem Res* 2017; 26(6): 1213–1227.